Exercise and Nutritional Supplementation (ENSASL)
Sarcopenia, Healthy Elderly, Healthy Young
About this trial
This is an interventional treatment trial for Sarcopenia
Eligibility Criteria
Inclusion Criteria:
- Inactive younger men (< 1 hour of formal exercise/week) in the overweight BMI category (25 - 29.9 kg/m2).
- Healthy older male participants will have a body mass index < 30 kg/m2, muscle mass index > 7.23 kg/m2, and a 4-meter walk test > 0.8 m/s.
- Men in the older adult "sarcopenia" group will be individuals that have a body mass index < 30 kg/m2, a muscle mass index between 8.51-10.75 kg/m2, and a 4-meter walk test < 0.8m/s.
Exclusion Criteria:
- Current smokers
- On more than one anti-diabetic drug
- Cardiovascular disease (myocardial infarction and/or hypertension requiring more than 2 medications)
- Congestive heart failure
- Renal disease (creatinine > 130)
- Previous stroke
- Hypertension requiring more than two-pharmacological agents
- Active musculoskeletal injuries and/or severe osteoarthritis
- Significant weight loss in the 3-month period prior to the study
- Vegan diet
- Dairy protein allergy
- History of muscle and/or bone wasting diseases
- Concurrent medications known to affect protein metabolism (i.e. corticosteroids, or prescription strength acne medications)
- Inability to consent
- Chronic obstructive pulmonary disease (FVC or FEV1 < 80% of age predicted mean value or requiring any medication other than a puffer as needed)
- Concurrent supplementation with a dietary protein, calcium, l-leucine, creatine, CoQ10, alpha lipoic acid, n-3 PUFA, and conjugated linoleic acid.
Sites / Locations
- McMaster University Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
No Intervention
No Intervention
Experimental
Multinutrient Supplement
Age biological and chronological
Sarcopenia grades
Exercise - home based programme
Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (protein and creatine sachet and omega-3 oil) or placebo during a 12 week home-based exercise program and we will assess the influence on the primary and secondary outcomes.
The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
Each of the older participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.